US Congress confirms new drug patent listing law

A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

More on this story

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

More on this story

Americas

AstraZeneca asks FDA to delay ANDAs for Crestor generics

14 June 2016 AstraZeneca has filed a citizen petition to the US Food and Drug Administration requesting it to wait until 2023 before approving generic versions of Crestor, a cholesterol treatment.

Americas

Diabetics to benefit under latest FDA biosimilar guidance

13 May 2019 The Food and Drug Administration has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

US Congress confirms new drug patent listing law

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features